General Information of Drug (ID: DMVGDSM)

Drug Name
3S,4R-293B Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
6604863
CAS Number
CAS 163163-25-5
TTD Drug ID
DMVGDSM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indapamide DMGN1PW Edema MG29 Approved [2]
L-768673 DMZ402C N. A. N. A. Terminated [3]
zinc pyrithione DMF0CRA Discovery agent N.A. Investigative [4]
XE991 DMLH1PK Discovery agent N.A. Investigative [5]
N-(3,3-Dimethyl-cyclopentyl)-4-hexyloxy-benzamide DM6EJQ4 Discovery agent N.A. Investigative [6]
(3R,4S)-293B DM47BEG Discovery agent N.A. Investigative [1]
HMR-1556 DMXMTA9 Discovery agent N.A. Investigative [7]
R-L3 DMGEDQJ Discovery agent N.A. Investigative [8]
N-(3,3-Dimethyl-butyl)-4-indol-1-yl-benzamide DMEUXOQ Discovery agent N.A. Investigative [6]
L-735,821 DMY60MG Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated potassium channel Kv7.1 (KCNQ1) TT846HF KCNQ1_HUMAN Blocker (channel blocker) [1]

References

1 A kinetic study on the stereospecific inhibition of KCNQ1 and I(Ks) by the chromanol 293B. Br J Pharmacol. 2001 Dec;134(8):1647-54.
2 Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84.
3 Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(... J Med Chem. 1997 Nov 21;40(24):3865-8.
4 Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96.
5 Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. Mol Pharmacol. 2000 Jun;57(6):1218-23.
6 Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers. J Med Chem. 2001 Nov 8;44(23):3764-7.
7 Selective optimization of side activities: another way for drug discovery. J Med Chem. 2004 Mar 11;47(6):1303-14.
8 A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents. Mol Pharmacol. 1998 Jul;54(1):220-30.
9 Molecular determinants of KCNQ1 channel block by a benzodiazepine. Mol Pharmacol. 2003 Jul;64(1):70-7.